Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin.

Chia-Sui Weng Chao-Chih WuTze-Chien ChenJen-Ruei ChenChueh-Yi HuangChih-Long Chang

Published in: Cancer management and research (2019)

Comparable outcomes in recurrent platinum-sensitive ovarian cancer treated with CD versus CP were presented in this study. Longer PFS in CD group was observed among patients with PFI for more than 12 months or in second recurrence.

Keyphrases

phase ii study
clinical trial
randomized controlled trial
metabolic syndrome
squamous cell carcinoma
cancer therapy
radiation therapy
glycemic control
skeletal muscle
weight loss